• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical and Prognostic Characteristics in Childhood Osteosarcoma: A Single-Center Experience in Türkiye.儿童骨肉瘤的临床和预后特征:土耳其的单中心经验
Turk Arch Pediatr. 2024 Sep 2;59(5):461-468. doi: 10.5152/TurkArchPediatr.2024.24043.
2
How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?初诊时的不确定肺部结节与高级别骨肉瘤患者的生存有何关联?
Clin Orthop Relat Res. 2021 Feb 1;479(2):298-308. doi: 10.1097/CORR.0000000000001491.
3
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon.黎巴嫩多学科背景下儿童骨肉瘤的临床预后因素与结局:局部控制延迟及坏死程度的影响
J Glob Oncol. 2019 Apr;5:1-8. doi: 10.1200/JGO.17.00241.
4
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.骨肉瘤新辅助化疗的预后因素及组织病理学反应分析。
Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14.
5
Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma?手术切缘是否影响肢体非转移性高级别骨肉瘤的局部复发和生存率?
Clin Orthop Relat Res. 2016 Mar;474(3):677-83. doi: 10.1007/s11999-015-4359-x.
6
Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?骨肉瘤患者仅通过化疗和取消手术就能治愈吗?
Cancer. 2002 Nov 15;95(10):2202-10. doi: 10.1002/cncr.10944.
7
Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?对于初诊时即发生转移的原发性骨恶性肿瘤患者,外科切除原发灶是否能提高总生存率?
Clin Orthop Relat Res. 2020 Oct;478(10):2284-2295. doi: 10.1097/CORR.0000000000001361.
8
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.肢体骨肉瘤伴同步肺转移的新辅助化疗:顺铂、阿霉素、大剂量甲氨蝶呤和异环磷酰胺治疗。
Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339.
9
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.诊断时的转移性骨肉瘤:预后因素及长期结局——法国儿科经验
Cancer. 2005 Sep 1;104(5):1100-9. doi: 10.1002/cncr.21263.
10
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.米法木肽联合标准化疗治疗高级别骨肉瘤的有效性:一项系统评价
JBI Database System Rev Implement Rep. 2017 Aug;15(8):2113-2152. doi: 10.11124/JBISRIR-2016-003105.

引用本文的文献

1
Delay in Diagnosis and Treatment of Bone Sarcoma-Systematic Review.骨肉瘤诊断和治疗的延迟——系统评价
Cancers (Basel). 2025 Mar 14;17(6):981. doi: 10.3390/cancers17060981.

本文引用的文献

1
Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017.骨肉瘤:1975 年至 2017 年基于监测、流行病学和最终结果计划的分析。
Cancer. 2022 Jun 1;128(11):2107-2118. doi: 10.1002/cncr.34163. Epub 2022 Feb 28.
2
Amputation Predisposes to Higher Cancer-Specific Mortality Than Limb Salvage Surgery in Pediatric Patients With Osteosarcoma of the Limbs: A Propensity Matching Analysis.肢体骨肉瘤患儿中,截肢比保肢手术更易导致更高的癌症特异性死亡率:一项倾向匹配分析。
Front Surg. 2022 Feb 9;9:817051. doi: 10.3389/fsurg.2022.817051. eCollection 2022.
3
Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients.小儿骨肉瘤患者化疗晚期毒性管理的当前见解
Cancer Manag Res. 2021 Dec 1;13:8989-8998. doi: 10.2147/CMAR.S287908. eCollection 2021.
4
Delay in diagnosis of primary osteosarcoma of bone in children: Have we improved in the last 15 years and what is the impact of delay on diagnosis?儿童原发性骨肉瘤的诊断延迟:在过去15年里我们是否有所改善,诊断延迟又有何影响?
J Bone Oncol. 2021 Mar 29;28:100359. doi: 10.1016/j.jbo.2021.100359. eCollection 2021 Jun.
5
Update on Osteosarcoma.骨肉瘤更新。
Curr Oncol Rep. 2021 Apr 21;23(6):71. doi: 10.1007/s11912-021-01053-7.
6
Future Directions in the Treatment of Osteosarcoma.骨肉瘤治疗的未来方向。
Cells. 2021 Jan 15;10(1):172. doi: 10.3390/cells10010172.
7
Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis.对于接受新辅助化疗的肢体骨肉瘤患者,保肢手术的五年生存率高于截肢手术。一项系统评价与荟萃分析。
J Bone Oncol. 2020 Sep 15;25:100319. doi: 10.1016/j.jbo.2020.100319. eCollection 2020 Dec.
8
Osteosarcoma.骨肉瘤。
Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28352. doi: 10.1002/pbc.28352. Epub 2020 Aug 11.
9
Molecular Biology of Osteosarcoma.骨肉瘤的分子生物学
Cancers (Basel). 2020 Jul 31;12(8):2130. doi: 10.3390/cancers12082130.
10
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.骨肉瘤的生存和预后:EURAMOS-1(欧洲和美国骨肉瘤研究)队列中 2000 多例患者的结果。
Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25.

儿童骨肉瘤的临床和预后特征:土耳其的单中心经验

Clinical and Prognostic Characteristics in Childhood Osteosarcoma: A Single-Center Experience in Türkiye.

作者信息

Altıntaş Mert, Cabi Ünal Emel, Taçyıldız Nurdan, İncesoy Özdemir Sonay, Uğur Dinçaslan Handan

机构信息

Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Türkiye.

Department of Pediatric Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye.

出版信息

Turk Arch Pediatr. 2024 Sep 2;59(5):461-468. doi: 10.5152/TurkArchPediatr.2024.24043.

DOI:10.5152/TurkArchPediatr.2024.24043
PMID:39440384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11391240/
Abstract

In our study, we aimed to share the clinical experiences of our center regarding osteosarcoma cases, the most common primary malignant bone tumor in children and adolescents. With approval from the Clinical Research Ethics Committee of our center, the data of 59 pediatric patients who were followed up in our center with the diagnosis of osteosarcoma between 2007 and 2021 were evaluated retrospectively. The mean time between the onset of symptoms and diagnosis was 3 months. Although not statistically significant, patients with a diagnostic delay of 3 months or less had a higher rate of recurrence and mortality. 59.3% of patients had metastatic disease, and the presence of metastases was associated with higher rates of recurrence and mortality. Significant number of patients had multiple surgical operations. Amputation as the first operation and the need for multiple surgeries were associated with higher mortality. Pathologically poor response to chemotherapy is associated with mortality. 42.4% of patients died, and the 5-year overall and disease-free survival rates were 47.5% and 30.5%, respectively. Survival rates were highest in non-metastatic and non-relapsed patients, and lowest in metastatic patients and patients with poor response to chemotherapy. Renal problems and cardiotoxicity were most frequently treatment-related complications. Significant improvements have been achieved in the survival and quality of life in osteosarcoma cases compared to previous years; however, there is still a long way to go, and more multicenter and multidisciplinary studies are needed on osteosarcoma.

摘要

在我们的研究中,我们旨在分享我们中心关于骨肉瘤病例的临床经验,骨肉瘤是儿童和青少年中最常见的原发性恶性骨肿瘤。经我们中心临床研究伦理委员会批准,对2007年至2021年间在我们中心接受随访诊断为骨肉瘤的59例儿科患者的数据进行了回顾性评估。症状出现与诊断之间的平均时间为3个月。虽然无统计学意义,但诊断延迟3个月或更短的患者复发率和死亡率较高。59.3%的患者有转移性疾病,转移的存在与更高的复发率和死亡率相关。相当数量的患者接受了多次手术。首次手术行截肢以及需要多次手术与更高的死亡率相关。化疗的病理反应差与死亡率相关。42.4%的患者死亡,5年总生存率和无病生存率分别为47.5%和30.5%。生存率在非转移性和未复发患者中最高,在转移性患者和化疗反应差的患者中最低。肾脏问题和心脏毒性是最常见的治疗相关并发症。与前几年相比,骨肉瘤病例的生存率和生活质量有了显著提高;然而,仍有很长的路要走,需要更多关于骨肉瘤的多中心和多学科研究。